原著論文Original Articles

2023年

ワクチン創成グループ 

  1. Morita M, Yoneda A, Tokunoh N, Masaki T, Shirakura K, Kinoshita M, Hashimoto R, Shigesada N, Takahashi J, Tachibana M, Tanaka S, Obana M, Hino N, Ikawa M, Tsujikawa K, Ono C, Matsuura Y, Kidoya H, Takakura N, Kubota Y, Doi T, Takayama K, Yoshioka Y, Fujio Y, Okada Y. Proc Natl Acad Sci U S A. 2023 Jan 17;120(3):e2213317120. doi: 10.1073/pnas.2213317120. Epub 2023 Jan 12. PMID: 36634143 Upregulation of Robo4 expression by SMAD signaling suppresses vascular permeability and mortality in endotoxemia and COVID-19 models.

  2. Nogimori T, Suzuki K, Masuta Y, Washizaki A, Yagoto M, Ikeda M, Katayama Y, Kanda H, Takada M, Minami S, Kobayashi T, Takahama S, Yoshioka Y, Yamamoto T. Front Immunol. 2023 Jan 4;13:1081047. doi: 10.3389/fimmu.2022.1081047. eCollection 2022. PMID: 36685601 Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination.

  3. Tokunoh N, Tamiya S, Watanabe M, Okamoto T, Anindita J, Tanaka H, Ono C, Hirai T, Akita H, Matsuura Y, Yoshioka Y. Front Immunol. A nasal vaccine with inactivated whole-virion elicits protective mucosal immunity against SARS-CoV-2 in mice.  in press

  4. Kawahara E, Yamamoto S, Shibata T, Hirai T,Yoshioka Y. CpG ODN enhances the efficacy of F protein vaccine against respiratory syncytial virus infection in the upper respiratory tract via CD4+ T cells. Biochem Biophys Res Commun. 2023 Oct 26:686:149143.

  5. Kawahara E, Shibata T, Hirai T, Yoshioka Y. Non-glycosylated G protein with CpG ODN provides robust protection against respiratory syncytial virus without inducing eosinophilia. Front Immunol. 2023 Dec 19;14:1282016.

  6. Kawai A, Tokunoh N, Kawahara E, Tamiya S, Okamura S, Ono C, Anindita J, Tanaka H, Akita H, Yamasaki S, Kunisawa J, Okamoto T, Matsuura Y, Hirai T, Yoshioka Y. Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses. J Clin Invest. 2023 Dec 1;133(23):e166827.

ウイルスワクチングループ 

  1. Arakawa M, Yoshida A, Okamura S, Ebina H, Morita E. Sci Rep. 2023 Jan 31;13(1):1753. doi: 10.1038/s41598-023-28984-4.PMID: 36720982 A highly sensitive NanoLuc-based protease biosensor for detecting apoptosis and SARS-CoV-2 infection. 
  2.  Hosomi K, Shimoyama A, Hinenoya A, Hatanaka N, Noguchi T, Ebina H, Tojima Y, Furuta M, Kondoh M, Kiyono H, Yamasaki S, Fukase K, Kunisawa J. Front Biosci (Landmark Ed). 2023 Jan 17;28(1):15. doi: 10.31083/j.fbl2801015.PMID: 36722281  Endotoxin-Free Stx2B-C-CPE Vaccine and Its Optimized Adjuvant Regimen for Preventing Food Poisoning. 
  3. Ishida K, Noguchi T, Kimura S, Suzuki H, Ebina H, Morita E. J Virol. 2023 Feb 28;97(2):e0163122. doi: 10.1128/jvi.01631-22. Epub 2023 Feb 7.PMID: 36749078 Tracking of Human Parvovirus B19 Virus-Like Particles Using Short Peptide Tags Reveals a Membrane-Associated Extracellular Release of These Particles.
  4. Okamura S, Yoshida A, Miyazato P, Matsumoto M, Ebina H. STAR Protoc. 2023 May 15;4(2):102352. doi: 10.1016/j.xpro.2023.102352. Online ahead of print.PMID: 37300825 Protocol to isolate temperature-sensitive SARS-CoV-2 mutants and identify associated mutations. 

 

TOP